【品名】奥贝（双氯芬酸钠缓释片剂）

【药理】奥贝(双氯芬酸钠缓释片)消炎.　镇痛.　解热.　消肿.

【适应症】奥贝(双氯芬酸钠缓释片)适应于类风湿关节炎、腰背痛、肩周炎、网球肘、强直性脊椎炎、急性痛风发作、软组织扭伤、骨关节炎和其它退行性关节病变，创伤及术后的疼痛与炎症、癌痛、牙痛、痛经、及耳鼻咽喉严重感染的辅助治疗，消肿、消炎、镇痛、解热。

【禁忌症】有活动性胃肠道病变（如消化性溃疡、出血）或近期内有胃肠道炎性疾病（如消化性溃疡、胃炎、局限性肠炎或溃疡性结肠炎）史者禁用；对双氯芬酸钠过敏或可疑过敏者禁用奥贝(双氯芬酸钠缓释片)既往服用乙酰水杨酸钠或其他非甾体类抗炎药曾诱发哮喘、鼻炎、荨麻疹等反应者禁用。

【不良反应】少见。但于服奥贝(双氯芬酸钠缓释片)期间出现下述不适时，请立即停药，并尽快去医院就诊。
胃肠道：少数患者可能出现腹部不适，恶心，呕吐；极个别人可能出现腹泻腹涨；发生胃、十二指肠出血者罕见。
皮肤：极少数患者可能出现皮疹，瘙痒，出现荨麻疹，紫癫者罕见。
中枢神经系统：个别患者有头晕，头痛，嗜睡，视物模糊等不适感觉。
过敏反应：罕见。
血液系统：个别患者可能会出现白细胞、血小板降低。
其他：极少数人可能出现尿异常；个别患者可能出现肝功能轻度异常，但停药后均可恢复。如出现其他不适，也请告诉医师，以妥善处理。

【注意事项】长期服用奥贝(双氯芬酸钠缓释片)者应定期检查血、尿常规、肝、肾功能；服药后出现神经系统不适者应避免进行机械操作和驾车。

【妊娠与哺乳期】在妊娠妇女中，不推荐使用。由于双氯芬酸钠分泌于乳汁的量极少，因此，不会对婴儿造成不良影响。

【药物相互作用】同时服用地高辛者应定期检查血地高辛水平；与新抗凝片合用时，应注意检查凝血功能；在少数情况下，需调整胰岛素和口服降糖药的剂量；与锂盐同时服用时，应调整锂盐的剂量；同时服用保钾利尿剂者，应定期监测血钾水平。

【用法与用量】服用双氯芬酸钠者可改为总量相同的奥贝(双氯芬酸钠缓释片)剂，每日一次一片，或遵医嘱，最好在餐后，整片用水服下。每日最大剂量不宜超过150mg。

【用药过量和中毒抢救】一旦发现服药过量，应立即停药并尽快送医院抢救。

【规格】75mg/片，100mg/片，缓释片

【包装】铝塑包装，75mg/片，肠溶缓释片，10片/盒，5片/盒，100mg/片，肠溶缓释片，10片/盒，5片/盒

【贮藏】室温、干燥

奥贝Apo-Diclo SR

成分
双氯芬酸钠 diclofenac Na

药物分类
解热镇痛药
抗风湿和消炎止痛药

适应症 
类风湿性关节炎、腰背痛、肩周炎、网球肘、强直性脊柱炎、急性痛风发作、软组织扭伤、骨关节炎和其他退行性关节病，创伤及手术后疼痛与炎症、癌痛、牙痛、痛经、及耳鼻喉严重感染的辅助治疗。

用量和用法 
75-100 mg qd，餐后整片用水吞服，最大剂量150 mg/日。

注意事项 
长期服药者应定期检查血、尿常规，肝、肾功能 ；服药后出现神经系统症状者应避免机械操作和驾车。妊娠妇女慎用。 

禁忌 
活动性胃肠道病变（如消化性溃疡、出血）或近期内有胃肠道炎性疾病（如胃炎、局限性肠炎或溃疡性结肠炎）史者 ；对双氯芬酸钠过敏或可疑过敏者 ；既往服用乙酰水杨酸或其他非甾体抗炎药曾诱发哮喘、鼻炎、荨麻疹者禁用。 

不良反应 
少数患者可出现腹部不适、恶心、呕吐、腹泻、腹胀 ；极个别患者可能出现皮疹、瘙痒、荨麻疹、紫癜 ；个别患者可出现头晕、头痛、嗜睡、视物模糊 ；罕见胃、十二指肠出血，过敏反应，白细胞及血小板减低，轻度肝功能异常。 

药物相互作用 
同时服用地高辛者应定期检查血地高辛水平 ；与抗凝剂合用时，应注意检查凝血功能 ；与口服降糖药、胰岛素和锂盐同时服用，需调整上述药物的剂量 ；同时服用保钾利尿剂者，应定期监测血钾水平。

Product: APO-DICLO SR  

Material Number: 40723
Active Ingredient: Diclofenac Sodium
Brand Reference: VOLTAREN® SR
 
Therapeutic Class (AHFS): Nonsteroidal Anti-inflammatory
   
Strength: 75 MG
DIN: 02162814
UPC: 771313-054515 
Pack Size (Form): 100 TABLET (BOTTLE)
 
Dosage Form: Tablet, Film Coated, Controlle 
Scored: NO 
Colour: Pink 
Shape: Triangular 
Markings: APO over 75
Route of Administration: Oral
Refrigeration Required: No 
Packaging Information:   Length Width Height Weight Unit/Case
Unit  4.50 cm  4.50 cm  7.70 cm  0.04 kg N/A
Case  18.00 cm  13.50 cm  7.70 cm  0.46 kg  12
Provincial Formulary Coverage: BC AB SK MB ON QC NB PE NS NL
Provincial Formulary Legend:  B Benefit (Non-Interchangeable) NB Not a Benefit
SA Special Authorization SAR Submission Awaiting Review
X Interchangeable    
APO-DICLO SR
Diclofenac sodium 75mg and 100mg Slow Release tablets.
Presentation
APO-DICLO SR 75mg tablet are pink, triangular in shape, 8.6mm x 8.1mm, with a film coating, identified APO over 75 on one side. Each tablet contains 75mg diclofenac sodium and typically weigh 202mg.
APO-DICLO SR 100 mg tablets are pink, round biconvex tablets 8.7mm in diameter, with a film coating, identified APO over 100 on one side, plain on the other side. Each tablet contains 100mg diclofenac sodium and typically weighs 268mg.
Uses
Actions
Diclofenac sodium is a nonsteroidal anti-inflammatory drug (NSAID) which exhibits anti-inflammatory, anti-rheumatic, analgesic and antipyretic activity. Its exact mode of action is not known but many of its actions appear to be associated with prostaglandins inhibition. Prostaglandins play a major role in the mediation of pain, inflammation and fever. Additional inhibitory effects on the formation and migration of other mediators of inflammation have also been proposed.
When used for symptomatic treatment, diclofenac sodium relieves pain and stiffness, reduces swelling and tenderness and in rheumatic diseases can improve grip strength and mobility.
When used for the relief of primary dysmenorrhoea, diclofenac sodium relieves the pain and reduces the extent of the bleeding.
APO-DICLO SR 75 and 100mg are suitable for patients for whom a daily dosage of 75-150mg is appropriate.
Pharmacokinetics
The presence of food does not affect the absorption of diclofenac from APO-DICLO SR tablets with peak plasma concentrations being reached after approximately 4 to 5 hours. Although the peak plasma concentration is lower than that achieved with the conventional dosage forms, the drug concentration in plasma and synovial fluid is sustained even when the drug levels following ingestion of the conventional form have dropped almost to baseline values.
No accumulation of diclofenac sodium was found following repeated once daily dosing of APO-DICLO SR 100mg or twice daily dosing of APO-DICLO SR 75mg tablets.
Diclofenac undergoes first-pass metabolism so that only 50-60% of a dose reaches the circulation and binding to plasma proteins is extensive (99.7%). The total apparent volume of distribution (Vd) is 0.12 to 0.1.7 L/kg and for central compartment Vd=0.04 L/kg.
Peak levels of diclofenac occur in the synovial fluid 2-4 hours after peak plasma concentrations have been reached but there is considerable inter-individual variation in the concentrations achieved with a given dose. Elimination from synovial fluid is less rapid (3 to 6 hours) than from plasma (1.5 to 2 hours). Diclofenac and its metabolites cross the placenta and small amounts distribute into breast milk.
Diclofenac is rapidly and extensively metabolised in the liver either by hydroxylation to phenolic metabolites with subsequent conjugation or by direct glucuronidation of the unchanged drug. Known phenolic metabolites are 3'-hydroxy-, 4'-hydroxy-, 5'-hydroxy-, 4',5-dihydroxy- and 3'hydorxy-4'-methoxy-diclofenac. Two of these metabolites are biologically active although to a much smaller extent than diclofenac with 4'-hydroxydiclofenac having 3% of the anti-inflammatory potency of diclofenac. Four of the metabolites including the active ones have short plasma half-lives of 1-3 hours although the virtually inactive 3'hydroxy-4'-methoxy-diclofenac has a much longer plasma half-life.
Approximately 60% of a dose is excreted in urine as either glucuronide conjugates or the metabolites. Less than 1% is excreted in the urine as free diclofenac. The balance of the dose is excreted in faeces within 96 hours.
Use in renal or chronic hepatic impairment: Dosage adjustments may need to be made when dysfunction is severe.
Indications
Diclofenac is used for the relief of moderate pain and inflammation in:
Rheumatic disorders: e.g. ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile rheumatoid arthritis, painful syndromes of the vertebral column, non-articular rheumatism.
Painful post-operative inflammation and swelling (including dental and orthopaedic procedures).
Painful or inflammatory gynaecological conditions e.g. primary dysmenorrhoea.
In keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. Diclofenac provides symptomatic relief but has not been shown to halt or reverse the underlying disease process. Fever alone is not an indication.
Dosage and Administration
After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest duration should be used.
Adults:
For moderate to severe acute pain: Daily doses of 100 mg to 150 mg administered as either one 75mg tablet twice daily or one 100mg tablet once daily.
For mild to moderate acute pain or long term chronic pain relief: either one 75mg tablet or one 100mg tablet once daily.
If symptoms are most pronounced during the night or in the morning, the tablets should be taken in the evening.
Tablets should be swallowed whole with liquid, preferably with food.
If long-term therapy is anticipated or the patient has a history of gastro-intestinal ulceration, it is advisable to take tablets with or after food to lessen the risk of duodenal ulceration.
Children:
APO-DICLO SR is not suitable for children because of its dosage strengths.
Elderly:
Dosage should be minimised and close monitoring is recommended.
Use in Impaired Renal Function:
Dosage reductions may be necessary when creatinine clearance is <10mL/min. In all cases of renal dysfunction, frequent monitoring is required.
Contraindications
Gastric or intestinal ulcer.
Known hypersensitivity to any component of the tablet.
Hypersensitivity to aspirin or other NSAIDs.
Patients with haemorrhagic diasthesis.
Patients in who attacks of asthma, urticaria or active rhinitis are precipitated by acetylsalicylic acid or other agents, which inhibit prostaglandin-synthetase activity.
Warnings and Precautions
Asthmatics: bronchospasm has been reported with the use of NSAIDs.
Due to the importance of prostaglandins in maintaining renal blood flow, caution is required in patients with impaired cardiac or renal function, the elderly, patients being treated with diuretics and patients with substantial extracellular volume depletion.
Diclofenac can cause retention of salt and water leading to oedema. Serum electrolytes should be monitored periodically during long term therapy.
Diclofenac should be used with caution in patients suffering from liver dysfunction.
Platelet aggregation may be inhibited temporarily. Patients with haemostasis defects should be carefully monitored.
Porphyria: Use of diclofenac should be avoided in patients with hepatic porphyria as it may trigger an attack.
Elevation of liver enzymes: Initial elevations are reversible. However, if they persist or worsen during prolonged therapy, diclofenac should be discontinued.
Allergic reactions: including anaphylaxis have occasionally been reported on first exposure to diclofenac.
Coumarin anticoagulants: (see Drug Interactions).
Prolonged treatment: Periodic blood counts are recommended.
Cardiovascular Thrombotic Events
Observational studies have indicated that non-selective NSAIDs may be associated with an increased risk of serious cardiovascular events, including myocardial infarction and stroke which may increase with dose or duration of use. Patients with cardiovascular disease or cardiovascular risk factors may also be at greater risk. To minimise the potential risk of an adverse cardiovascular event in patients taking an NSAID, especially in those with cardiovascular risk factors, the lowest effective dose should be used for the shortest possible duration (see Dosage and Administration).
There is no consistent evidence that the concurrent use of aspirin mitigates the possible increased risk of serious cardiovascular thrombotic events associated with NSAID use.
Hypertension
NSAIDs may lead to the onset of new hypertension or worsening of pre-existing hypertension and patients taking anti-hypertensives with NSAIDs may have an impaired anti-hypertensive response. Caution is advised when prescribing NSAIDs to patients with hypertension. Blood pressure should be monitored closely during initiation of NSAID treatment and at regular intervals thereafter.
Heart failure
Fluid retention and oedema have been observed in some patients taking NSAIDs; therefore caution is advised in patients with fluid retention or heart failure.
Gastrointestinal Events
All NSAIDs can cause gastrointestinal discomfort and rarely serious, potentially fatal gastrointestinal effects such as ulcers, bleeding and perforation, which may increase with dose or duration of use but can, occur at any time without warning. Upper GI ulcers, gross bleeding or perforation caused by NSAIDs occur approximately 1% of patients treated for 3-6 months and in about 2-4% patents treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.
Caution is advised in patients with risk factors for gastrointestinal events who may be at greater risk of developing serious gastrointestinal events, e.g. the elderly, those with a history of serious gastrointestinal events, smoking and alcoholism. When gastrointestinal bleeding or ulcerations occur in patients receiving NSAIDs, the drug should be withdrawn immediately. Doctors should warn patients about the signs and symptoms of serious gastrointestinal toxicity.
The concurrent use of aspirin and NSAIDs also increases the risk of serious gastrointestinal adverse events.
Severe Skin Reactions
NSAIDs may rarely cause serious cutaneous adverse events such as exfoliative dermatitis, toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), which can be fatal and occur without warning. These serious adverse events are idiosyncratic and are independent of dose or duration of use. Patients should be advised of the signs and symptoms of serious skin reactions and to consult their doctor at the first appearance of a skin rash or any sign of hypersensitivity.
Mutagenicity, Carcinogenicity and Teratogenicity
Studies of use of diclofenac in rats did not show any effect on the fertility of adult rats nor in the pre-, peri- and postnatal development of their offspring. No teratogenic effects were detected in mice, rats or rabbits. No mutagenic effects were observed in in vitro or in vivo experiments. No carcinogenic potential was detected in long term studies in rats and mice.
Use during Pregnancy
Category C.
Diclofenac should be avoided in pregnancy unless the benefits outweigh the potential risk to the foetus. This applies particularly to the last 3 months of pregnancy when in common with other prostaglandin syntheses inhibitors, diclofenac may cause closure of the foetal ducts arterioles, foetal renal impairment, inhibition of platelet aggregation and delay labour and birth.
Use in nursing mothers
Diclofenac is detected in breast milk following doses of 50 mg every 8 hours, but amounts are so small that no undesirable effects on the baby are likely.
Effects on ability to drive or use machinery
Diclofenac may cause some patients to become dizzy, light-headed or less alert. Patients should be aware of their reaction to Diclofenac before driving or using machinery.
Adverse Effects
Gastrointestinal, dermatological and central nervous system adverse effects are the most common seen. Most diclofenac-induced adverse effects occur during the first 3 to 6 months of treatment and are usually mild and transient.
Gastrointestinal effects:
May require discontinuation of diclofenac in a small number of patients.
Common: (>1%) Epigastric or abdominal discomfort, pressure, heaviness or distension; epigastric, gastric or abdominal pain; nausea; anorexia; diarrhoea, vomiting, flatulence, constipation or eruction.
Infrequent: (0.1-1%) Gastric and duodenal ulcerations and bleeding
Rare: (<0.1%) Hyperacidity, stomatitis, coated tongue, peptic ulcer with perforation, lower gut disorders e.g. non-specific haemorrhagic colitis, exacerbation of ulcerative colitis and Crohn's disease; oesophageal lesions.
Central Nervous System:
Common: (>1%) Dizziness, headache, vertigo, malaise, insomnia, drowsiness, impaired concentration, impaired vision.
Rare: (<0.1%) Irritability, sweating, tiredness, sensory disturbances, tinnitus, convulsions, memory disturbances, disorientation, depression, anxiety, psychosis, tremor and taste disorders.
Dermatological reactions:
Common: (>1%) Rash, pruritus
Infrequent: (0.1-1.0%) Skin eruption, urticaria, erythema
Rarely: (<0.1%) alopecia, photosensitivity, bullous eruption, purpura, erythema multiforme, Stevens-Johnson syndrome, Lyell's syndrome, eczema and exfoliate dermatitis.
Renal:
Common: (>1%) Fluid and water retention; oedema with or without weight gain
Rare: (<0.1%) Haematuria; proteinuria, interstitial nephritis, papillary necrosis, nephrotic syndrome, acute renal failure.
Hepatic:
Common: (>1%) Elevation of transaminase enzymes (AST and ALT) which is usually transient.
Infrequent: (0.1-1%) Hepatitis with or without jaundice
Rare: (<0.1%) Fulminant hepatitis.
Haematological:
Rare: (<0.1%) Anaemia in some patients, secondary to GI bleeding; decreased platelet aggregation; leucopenia; thrombocytopenia; haemolytic anaemia; aplastic anaemia; agranulocytosis.
Hypersensitivity Reactions:
Infrequent: (0.1-1%) Bronchospasm or asthma; anaphylactic reactions, hypotension.
Rare: (<0.1%) Vasculitis, pneumonia
Cardiovascular:
Common: (>1%) Palpitations, angina, arrhythmias
Rare: (<0.1%) Exacerbation of cardiac failure
Interactions
Antihypertensive Agents: Diclofenac can reduce the antihypertensive effects of propranolol and other β-blockers as well as other antihypertensive agents.
Coumarin anticoagulants: There have been isolated reports of an increased risk of haemorrhage with the combination of warfarin and NSAIDs. Although the risk is reported to be low for diclofenac, careful monitoring of the INR or Prothrombin Time is required because diclofenac may cause GI bleeding and can inhibit platelet aggregation.
Diuretics: NSAIDs may reduce the activity of diuretics.
Potassium-sparing diuretics: concurrent administration with diclofenac has resulted in elevations of serum potassium levels; careful monitoring is advised.
Digoxin, lithium and cyclosporin: Diclofenac may cause increased concentrations of these agents, with the potential for adverse side effects or toxicity. Frequent monitoring is necessary, especially in those with renal impairment.
Hypoglycaemic agents: Studies indicate that diclofenac does not potentiate the effects of oral hypoglycaemic. However, there have been isolated reports of both hypoglycaemia and hyperglycaemia.
Methotrexate: The combination of diclofenac and methotrexate has resulted in serious methotrexate toxicity which has sometimes been fatal. The risk is greatest if patients are taking high (anti-neoplastic) doses of methotrexate or if they have renal impairment. Caution is needed when diclofenac is administered 24 hours before or after treatment with methotrexate.
NSAIDS: Concomitant administration of systemic NSAIDs may increase the frequency of adverse effects.
Quinolones: Isolated reports suggest that quinolones (e.g. ciprofloxacin, norfloxacin) and NSAIDs could increase the risk of seizures. Although a causal relationship is still uncertain, caution is recommended.
Laboratory Tests: Diclofenac increases platelet aggregation time but does not affect bleeding time, plasma thrombin clotting time, plasma fibrinogen or factors V and VII to XII. Statistically significant changes in thrombin and partial thromboplastin times have been reported in normal volunteers. The mean changes were observed to be less than 1 second in both instances and are unlikely to be clinically important.
Persistent abnormal or worsening renal, hepatic or haematological test results should be followed up carefully since they may be related to therapy.
Overdosage
There is no typical clinical picture resulting from an overdosage with diclofenac.
Management consists of supportive and symptomatic measures. Absorption should be prevented by inducing emesis or by gastric lavage, followed by administration of activated charcoal. Supportive and symptomatic treatment should be given if there are signs of hypotension, renal failure, convulsions, GI bleeding and respiratory depression.
Therapies such as forced diuresis, dialysis or haemoperfusion are likely to be ineffective.
Pharmaceutical Precautions
Shelf life 36 months from date of manufacture
Store below 30 °C.
Protect from heat, light and moisture.
Keep out of reach of children.
Medicine Classification
Prescription-Only medicine.
Package Quantities
APO-DICLO SR 75mg tablets
Bottles of 100 and 500 tablets
Blister packs of 30, 60, 90, 100, 500 and 1000 tablets
APO-DICLO SR 100mg tablets:
Bottles of 100 and 500 tablets.
Blister packs of 30, 60, 90, 100, 500 and 1000 tablets.
Further Information
Contains Dextrates.
Prepared by
APOTEX NZ LTD
32 Hillside Road
Glenfield, Auckland
Private Bag 102995
North Shore Mail Centre
Tel: (09) 444 2073
Fax: (09) 444 2951
Date of Preparation
14 August 2007
【原产地英文商品名】:APO-DICLO 50MG/pill 30pills/bottle
【原产地英文药品名】:DICLOFENAC
【中文参考商品译名】:奥贝 50毫克/片 30片/瓶
【中文参考药品译名】:双氯芬酸
【生产厂家中文参考译名】:诺华
【生产厂家英文名】:NOVARTIS